Gyre Therapeutics (GYRE) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Gyre Therapeutics (GYRE) overview

Gyre Therapeutics (GYRE) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 117m and operating profit of USD 11.5m; the year-end share price was 7.06 USD and market capitalisation was USD 645m. Gyre Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Gyre Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 106mFY 2025
Share price7.06 USDFY 2025 year end
RevenueUSD 117mFY 2025
Operating profitUSD 11.5mFY 2025
Net earningsUSD 5.0mFY 2025
Market capitalisationUSD 645mFY 2025 year end

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company combining a commercial fibrosis-drug business in China with global research and development. Its subsidiary markets ETUARY, Etorel and Contiva for pulmonary fibrosis, other interstitial lung diseases and thrombocytopenia indications. Following its 2026 acquisition of Cullgen, Gyre also develops targeted protein degrader and degrader-antibody conjugate therapies for cancer and inflammatory diseases.

Generate the Gyre Therapeutics report

Gyre Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Gyre Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Gyre Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.